Design, synthesis and systematic evaluation of cytotoxic 3-heteroarylisoquinolinamines as topoisomerases inhibitors

European Journal of Medicinal Chemistry

Volumn 82, Issue , 2014, Pages 181-194

  My Van, Hue Thi ^a,d   Woo, Hyunjung ^b   Jeong, Hyung Min ^a   Khadka, Daulat Bikram ^a   Yang, Su Hui ^a   Zhao, Chao ^a   Jin, Yifeng ^a   Lee, Eung Seok ^c   Youl Lee, Kwang ^a   Kwon, Youngjoo ^b   Cho, Won Jea ^a  

^a Chonnam National University   (South Korea)

^b Ewha Womans University   (South Korea)

^c Yeungnam University   (South Korea)

^d HANOI UNIVERSITY OF PHARMACY   (Viet Nam)

Author keywords

3 Heteroarylisoquinolinamine; Cell cycle arrest; Molecular docking; Selective cytotoxicity; Topoisomerase I; Topoisomerase II

Indexed keywords

1 (4 ETHYL PIPERAZIN 1 YL) 3 THIOPHEN 2 YL ISOQUINOLINE; 1 (4 ETHYL PIPERAZIN 1 YL) 6 METHYL 3 THIOPHEN 2 YL ISOQUINOLINE; 1 (4 METHYL PIPERAZIN 1 YL) 3 THIOPHEN 2 YL ISOQUINOLINE; 1 AZIDO 5 METHYL 3 THIOPHEN 2 YL ISOQUINOLINE; 1 CHLORO 3 (1,5 DIMETHYL 1H PYRROL 2 YL) 5 METHYL ISOQUINOLINE; 1 CHLORO 3 THIOPHEN 2 YL ISOQUINOLINE; 1 CHLORO 5 METHYL 3 THIOPHEN 2 YL ISOQUINOLINE; 1 CHLORO 6 METHYL 3 THIOPHEN 2 YL ISOQUINOLINE; 1 CHLORO 7 METHYL 3 THIOPHEN 2 YL ISOQUINOLINE; 1 MORPHOLIN 4 YL 3 THIOPHEN 2 YL ISOQUINOLINE; 1 PIPERAZIN 1 YL 3 THIOPHEN 2 YL ISOQUINOLINE; 1 PIPERIDIN 1 YL 3 THIOPHEN 2 YL ISOQUINOLINE; 3 (1,5 DIMETHYL 1H PYRROL 2 YL) 5 METHYL 2H ISOQUINOLIN 1 ONE; 3 THIOPHEN 2 YL 2H ISOQUINOLIN 1 ONE; 3 THIOPHEN 2 YL ISOQUINOLIN 1 YLAMINE; 5 METHYL 3 THIOPHEN 2 YL 2H ISOQUINOLIN 1 ONE; 6 METHYL 1 (4 METHYL PIPERAZIN 1 YL) 3 THIOPHEN 2 YL ISOQUINOLINE; 6 METHYL 1 MORPHOLIN 4 YL 3 THIOPHEN 2 YL ISOQUINOLINE; 6 METHYL 1 PIPERAZIN 1 YL 3 THIOPHEN 2 YL ISOQUINOLINE; 6 METHYL 1 PIPERIDIN 1 YL 3 THIOPHEN 2 YL ISOQUINOLINE; 6 METHYL 3 THIOPHEN 2 YL 2H ISOQUINOLIN 1 ONE; 7 METHYL 1 PIPERIDIN 1 YL 3 THIOPHEN 2 YL ISOQUINOLINE; 7 METHYL 3 THIOPHEN 2 YL 2H ISOQUINOLIN 1 ONE; AMINE; BENZYL (6 METHYL 3 THIOPHEN 2 YL ISOQUINOLINE 1 YL)AMINE; CAMPTOTHECIN; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); GYRASE INHIBITOR; HETEROCYCLIC COMPOUND; ISOQUINOLINE DERIVATIVE;

ANIMAL CELL; APOPTOSIS; ARTICLE; BINDING AFFINITY; BREAST CANCER CELL LINE; CELL CYCLE ARREST; CELL CYCLE PHASE; COLORECTAL CANCER CELL LINE; COLORECTAL CARCINOMA; CONTROLLED STUDY; DNA CLEAVAGE; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; ENZYME ACTIVITY; FEMALE; FLOW CYTOMETRY; HELA CELL LINE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HYDROGEN BOND; IC 50; MOLECULAR DOCKING; MOUSE; NONHUMAN; PROSTATE CANCER CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; METABOLISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL LINE; X RAY CRYSTALLOGRAPHY;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CRYSTALLOGRAPHY, X-RAY; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HETEROCYCLIC COMPOUNDS; HUMANS; ISOQUINOLINES; MODELS, MOLECULAR; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP; TOPOISOMERASE I INHIBITORS; TOPOISOMERASE II INHIBITORS;

EID: 84902155414     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2014.05.047     Document Type: Article

References (25)

1. J.C. Wang Annu. Rev. Biochem. 65 1996 635 692
2. J.J. Champoux Annu. Rev. Biochem. 70 2001 369 413
3. J.C. Wang Nat. Rev. Mol. Cell. Biol. 3 2002 430 440
4. Y. Pommier Chem. Rev. 109 2009 2894 2902
5. D.B. Khadka, and W.J. Cho Expert Opin. Ther. Patents 23 2013 1033 1056
6. I. Husain, J.L. Mohler, H.F. Seigler, and J.M. Besterman Cancer Res. 54 1994 539 546
7. T.D. Pfister, W.C. Reinhold, K. Agama, S. Gupta, S.A. Khin, R.J. Kinders, R.E. Parchment, J.E. Tomaszewski, J.H. Doroshow, and Y. Pommier Mol. Cancer Ther. 8 2009 1878 1884
8. W.C. Reinhold, J.L. Mergny, H. Liu, M. Ryan, T.D. Pfister, R. Kinders, R. Parchment, J. Doroshow, J.N. Weinstein, and Y. Pommier Cancer Res. 70 2010 2191 2203
9. Y.L. Janin, A. Croisy, J.F. Riou, and E. Bisagni J. Med. Chem. 36 1993 3686 3692
10. W.J. Cho, Q.M. Le, H.T. My Van, K. Youl Lee, B.Y. Kang, E.S. Lee, S.K. Lee, and Y. Kwon Bioorg. Med. Chem. Lett. 17 2007 3531 3534
11. D.B. Khadka, Q.M. Le, S.H. Yang, H.T. Van, T.N. Le, S.H. Cho, Y. Kwon, K.T. Lee, E.S. Lee, and W.J. Cho Bioorg. Med. Chem. 19 2011 1924 1929
12. W.J. Cho, M.J. Park, B.H. Chung, and C.O. Lee Bioorg. Med. Chem. Lett. 8 1998 41 46
13. W.J. Cho, S.Y. Min, T.N. Le, and T.S. Kim Bioorg. Med. Chem. Lett. 13 2003 4451 4454
14. K.E. Kim, W.J. Cho, T.S. Kim, B.H. Kang, S.J. Chang, C.H. Lee, and D.D. Kim Drug. Dev. Ind. Pharm. 28 2002 889 895
15. K.E. Kim, W.J. Cho, S.J. Chang, C.S. Yong, C.H. Lee, and D.D. Kim Int. J. Pharm. 217 2001 101 110
16. T.N. Le, S.H. Yang, D.B. Khadka, H.T. Van, S.H. Cho, Y. Kwon, E.S. Lee, K.T. Lee, and W.J. Cho Bioorg. Med. Chem. 19 2011 4399 4404
17. K.Y. Jun, E.Y. Lee, M.J. Jung, O.H. Lee, E.S. Lee, H.Y. Park Choo, Y. Na, and Y. Kwon Eur. J. Med. Chem. 46 2011 1964 1971
18. T. Nakumura, T. Sakaeda, N. Ohmoto, Y. Moriya, C. Komoto, T. Shirakawa, A. Gotoh, M. Matsuo, and K. Okmura Pharm. Res. 20 2003 324 327
19. G. Zhao, J. Huang, K. Xue, L. Si, and G. Li Eur. J. Pharm. Sci. 50 2013 429 439
20. F. Shen, S. Chu, A.K. Bence, B. Bailey, X. Xue, P.A. Erickson, M.H. Montrose, W.T. Beck, and L.C. Erickson J. Pharmacol. Exp. Ther. 324 2008 95 102
21. B.L. Staker, K. Hjerrild, M.D. Feese, C.A. Behnke, A.B. Burgin Jr., and L. Stewart Proc. Natl. Acad. Sci. U.S.A 99 2002 15387 15392
22. C.-C. Wu, Y.-C. Li, Y.-R. Wang, T.-K. Li, and N.-L. Chan Nucl. Acids Res. 41 2013 10630 10640
23. X. Xiao, and M. Cushman J. Am. Chem. Soc. 127 2005 9960 9961
24. B.L. Staker, M.D. Feese, M. Cushman, Y. Pommier, D. Zembower, L. Stewart, and A.B. Burgin J. Med. Chem. 48 2005 2336 2345
25. K.S. Chung, H.E. Choi, J.S. Shin, Y.W. Cho, J.H. Choi, W.J. Cho, and K.T. Lee Carcinogenesis 34 2013 1852 1860